Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Ironwood licenses worldwide rights to Depomed's Acuform drug delivery technology

Ironwood Pharmaceuticals, Inc. and Depomed, Inc. today announced that Ironwood has licensed worldwide rights to utilize Depomed's Acuform gastric retentive drug delivery technology for an Ironwood early stage development program, continuing Ironwood's efforts to augment its development pipeline beyond linaclotide.

28 Jul 2011

BD to acquire Carmel Pharma

BD, a leading global medical technology company, announced today that it signed a definitive agreement to acquire Carmel Pharma, Inc., a Swedish company that manufactures the PhaSeal System, the leading closed-system drug transfer device for the safe handling of hazardous drugs that are packaged in vials.

From BD (Becton, Dickinson and Company) 28 Jul 2011

Invaron, Columbia Laboratories enter license agreement for STRIANT buccal system

Columbia Laboratories, Inc. has entered into a license agreement with Invaron Pharmaceuticals Inc., a privately-held Canadian pharmaceutical company, for STRIANT in Canada.

27 Jul 2011

Nano-emulsion shows promise for Viagra patch

Sildenafil citrate, commonly known as Viagra, is currently the first choice drug for erectile dysfunction but despite its success oral delivery of the drug is hampered by numerous side effects, the long delay before it starts working and the short amount of time it lasts. Researchers in Egypt think they may have a solution via nanotechnology.

27 Jul 2011

Cipher net revenue decreases to $0.7 million for Q2 2011

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three and six months ended June 30, 2011.

26 Jul 2011

Debiopharm, INC Research partner for clinical development programmes

INC Research, LLC, a therapeutically focused contract research organisation (CRO) with a trusted process for delivering reliable results, and Debiopharm Group, a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, today announced a strategic partnership.

26 Jul 2011

'Core-shell' nanoparticles for effective intracellular delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, together with collaborators at the Massachusetts Institute of Technology (MIT), announced today the publication of new paper describing discovery of "core-shell" nanoparticles for systemic delivery of RNAi therapeutics.

26 Jul 2011

Valeritas' V-Go Disposable Insulin Delivery Device receives CE Mark approval

Valeritas, Inc., a medical technology company focused on the development and commercialization of innovative drug delivery solutions, announced today it received CE Mark approval for its V-Go Disposable Insulin Delivery Device as well as ISO 13485: 2003 Quality Management System Certification.

25 Jul 2011

BDSI completes BEMA Buprenorphine Phase 3 trial on chronic pain

BioDelivery Sciences International, Inc. announced today that the last patient has completed the randomized portion of its Phase 3 clinical trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain, signifying completion of the trial.

25 Jul 2011

Alliqua acquires global license for wound care dressings from Noble Biomaterials

Alliqua, Inc., an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and wound care technologies today announced that it has acquired from Noble Biomaterials, Inc. a 10 year exclusive global license for two wound care dressings, with an additional 10 year renewal option.

21 Jul 2011

Caltech, Zcube collaboration will bring painless transdermal drug delivery to patients

Zcube Srl, a research venture of the Italian pharmaceutical company Zambon, and the California Institute of Technology (Caltech) have signed an exclusive research and option agreement to develop and commercialize skin patches that contain embedded carbon nanotubes for delivering drugs. The patches will first be developed to painlessly administer drugs through the skin; other applications are envisioned for future use. Mory Gharib, Hans W. Liepmann Professor of Aeronautics and professor of bioinspired engineering, is the principal investigator at Caltech.

21 Jul 2011

Partners of Bacterial Vaginosis sufferers at increased risk of HIV

Starpharma Holdings Limited today commented on results of a study which showed that men were three times more likely to contract HIV from their female partners if the women also had bacterial vaginosis (BV) in the three months before the men became infected.

18 Jul 2011

CVS Caremark adds Access' MuGard to pharmacy benefit network

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that its lead product for oral mucositis, MuGard, has been added to CVS Caremark's pharmacy benefit network.

15 Jul 2011

Michael J. Fox Foundation awards Impax $400,000 grant for research of IPX066 for Parkinson’s disease

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., has been awarded funding of up to $400,000 by The Michael J. Fox Foundation for ongoing clinical research of the Company's investigational carbidopa-levodopa extended release (CD-LD ER) product IPX066, which is intended to treat the motor symptoms of Parkinson's disease (PD).

14 Jul 2011

Gerresheimer second quarter revenues increase 5.9% to EUR 284.5m

Gerresheimer AG, one of the leading global suppliers to the pharma and healthcare industry, has closed successfully the second quarter of the 2011 financial year

13 Jul 2011

Two papers highlight therapeutic potential of human Sertoli cells

Two papers published in the current issue of Cell Transplantation, now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/, highlight the therapeutic potential of human Sertoli cells that are present in the testes and are also called "nurse" or "mother" cells because they nurture the developing sperm cells.

12 Jul 2011

FDA-approved Zuplenz oral soluble film now available for licensing to new commercial partners

MonoSol Rx, a specialty pharmaceutical company and the developers of the PharmFilm technology platform, in collaboration with APR Applied Pharma Research s.a. of Switzerland, announced today that its FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble film is available for licensing to new commercial partners.

11 Jul 2011

Drug Delivery News and Research

Further Reading

Ironwood licenses worldwide rights to Depomed's Acuform drug delivery technology

BD to acquire Carmel Pharma

Invaron, Columbia Laboratories enter license agreement for STRIANT buccal system

Nano-emulsion shows promise for Viagra patch

Cipher net revenue decreases to $0.7 million for Q2 2011

Debiopharm, INC Research partner for clinical development programmes

'Core-shell' nanoparticles for effective intracellular delivery of RNAi therapeutics

Valeritas' V-Go Disposable Insulin Delivery Device receives CE Mark approval

BDSI completes BEMA Buprenorphine Phase 3 trial on chronic pain

Alliqua acquires global license for wound care dressings from Noble Biomaterials

Caltech, Zcube collaboration will bring painless transdermal drug delivery to patients

Partners of Bacterial Vaginosis sufferers at increased risk of HIV

CVS Caremark adds Access' MuGard to pharmacy benefit network

Michael J. Fox Foundation awards Impax $400,000 grant for research of IPX066 for Parkinson’s disease

Gerresheimer second quarter revenues increase 5.9% to EUR 284.5m

Two papers highlight therapeutic potential of human Sertoli cells

FDA-approved Zuplenz oral soluble film now available for licensing to new commercial partners

Generex announces convertible preferred stock securities purchase agreement

Preliminary results from Generex Oral-lyn clinical trial on type 1 diabetes

Top-line results from HyQ subcutaneous IG phase III study in patients with primary immunodeficiency

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo